|
Sinoway Industrial Co.Ltd.
|
Product name
|
Bivalirudin Acetate
|
CAS No.
|
128270-60-0
|
Synonyms
|
BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;Bivalirudin, TFA;BITTERMELONP.E;Human Bivalirudin;Bivalirudin Acetate;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH trifluoroacetate salt
|
Molecular Formula
|
C98H138N24O33
|
Molecular Weight
|
2180.29
|
Quality Standard
|
98% up by HPLC, USP, cGMP, DMF
|
Appearance
|
white to off-white crystalline powder
|
Items
|
Specifications
|
Results
|
Appearance
|
White or almost white crystalline powder
|
White powder
|
Assay (by HPLC)
|
98%-102%
|
99.34%
|
Identification
|
Positive
|
Positive
|
Absorbance(E1cm)
|
465-495
|
482.5
|
Melting point
|
191。C - 195。C
|
93.5。C-195。C
|
Loss on drying
|
< 0.5%
|
0.19%
|
Specific rotation
|
+288。-298。
|
290.2。
|
Residue on ignition
|
< 0.10%
|
0.03%
|
Related substances
|
Total related substances < 1.5%
|
< 1.3%
|
Single related substances < 0.5%
|
< 0.4%
|
Residue solvents
|
< 0.2%
|
0.10%
|
Heavy metals
|
< 20 ppm
|
< 10 ppm
|
Conclusion
|
Meet the specification of enterprise standard
|
Function of Bivalirudin
Bivalirudin is a synthetic anticoagulant. It is an analog of naturally occurring hirudin. It is a polypeptide composed of 20 amino acids. It can bind to thrombin with high affinity and specifically inhibit the activity of thrombin. The reaction catalyzed and induced by thrombin. Bivalirudin can not only bind to free thrombin in plasma, but also bind to thrombin linked to blood clots. This binding is reversible and does not require the presence of ATⅢ. Bivalirudin has a strong anticoagulant effect, and has antithrombotic effect on a variety of animal arterial and venous models. Bivalirudin can prolong partial thromboplastin time (APTT), thrombin time (PT) and activated clotting time (ACT).
Bivalirudin is suitable for patients with unstable angina and unstable angina pectoris undergoing PTCA; percutaneous intervention in acute ischemic coronary complications.
|
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
